Join to View Full Profile
200 First Street SWRochester, MN 55905
Phone+1 507-773-0487
Dr. Carr is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- I am a board certified medical oncologist specializing in treatment of patients with gastrointestinal malignancies with a focus on pancreatic cancer. I completed my training as a Clinical Investigator at Mayo Clinic in Rochester, MN. My research interests revolve around using the first principles of evolutionary ecology to better understand and treat pancreatic cancer. Thus, these interests range from the level of the cancer genome and epigenetic regulation, to the tumor microenvironment, and the development of adaptive therapies informed by evolutionary dynamics of tumors.
Clinical Expertise
- Gastrointestinal cancer, Pancreatic cancer
Education & Training
Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 2018 - 2021- Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 2015 - 2018
University of Illinois College of MedicineClass of 2015
University of Illinois Champaign-UrbanaBS, Molecular and Cellular Biology, Summa Cum Laude, 2004 - 2008
Certifications & Licensure
MN State Medical License 2016 - 2025
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- ASCO Conquer Cancer Young Investigator Award Conquer Cancer Foundation, Alexandria, VA, 2022
- Mayo Foundation Scholar Mayo Clinic, Rochester, MN, 2021
- Top Performing Provider Award Mayo Clinic, Rochester, MN, 2020-2021
- Join now to see all
Clinical Trials
- A Phase 1/2a Study of IMM-1-104 in Participants With Previously Treated, RAS-Mutant, Advanced or Metastatic Solid Tumors Start of enrollment: 2022 Oct 31
- Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Start of enrollment: 2024 Oct 16
- Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma Start of enrollment: 2024 Dec 13
- Join now to see all
Publications & Presentations
PubMed
- Discordant risk factors between pancreatic neuroendocrine neoplasms and pancreatic ductal adenocarcinoma.Shruti Chandra, Thorvardur R Halfdanarson, Erin E Carlson, Kari G Rabe, Amit Mahipal
Endocrine-Related Cancer. 2025-04-01 - Molecular KRAS ctDNA Predicts Metastases and Survival in Pancreatic Cancer: A Prospective Cohort Study.Jennifer L Leiting, Roberto Alva-Ruiz, Jennifer A Yonkus, Amro M Abdelrahman, Isaac T Lynch
Annals of Surgical Oncology. 2025-03-11 - KRAS Promotes GLI2-Dependent Transcription during Pancreatic Carcinogenesis.Ashley N Sigafoos, Ezequiel J Tolosa, Ryan M Carr, Maite G Fernandez-Barrena, Luciana L Almada
Cancer Research Communications. 2024-07-01
Press Mentions
‘The Biggest Treasure Hunt You Can Imagine’: Inside the Digitization of Mayo Clinic’s Tissue Registry ArchiveAugust 19th, 2024
Experimental approach to treating pancreatic cancer heralded as a successJune 1st, 2022
Grant Support
- Epigenetics of Pancreatic CancerElsa U. Pardee Foundation2023–2024
- Use of Transcriptomic Signatures to Predict Personalized Gemcitabine Sensitivity in Pancreatic Cancer TreatmentASCO Conquer Cancer Foundation2022–2023
Professional Memberships
- Member
- Member
- International Society for Evolution, Ecology and CancerMember
- Member
External Links
- Carr Labhttp://www.carr-lab.com
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
